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Introduction
Chronic lymphocytic leukaemia (CLL) is the most common type of leukaemia occurring in the Western world [1] . The age standardised incidence rate in the Netherlands is 3.8 per 100,000 [2] . Five-year relative overall survival (OS) increased from 61% in 1989-1993 to 70% in 2004-2008 for males, and for females from 71% to 76%. The majority of the patients diagnosed with CLL are above 65 years and have comorbidities.
A wait and see approach is common for Dutch patients diagnosed with CLL [3] . However, eventually many patients receive treatment. Currently, in the Netherlands, fludarabine, cyclophosphamide and rituximab is the recommended regimen for fit patients, i.e. patients without comorbidities, usually younger than 65-70 years. Chlorambucil plus a monoclonal antibody is recommended for less fit patients, i.e. patients with some comorbidities and/or WHO performance status 0-2. For unfit patients, i.e patients with several comorbidities and/or WHO performance status 3-4, chlorambucil or chlorambucil plus a monoclonal antibody is recommended [4] . There are several monoclonal antibodies available for newly diagnosed patients with CLL such as rituximab, obinutuzumab and ofatumumab. The efficacy of these therapies was investigated in randomised phase III studies, i.e. the CLL11 [5] and COMPLEMENT 1 [6] . The CLL11 study was a three arm phase III http://dx.doi.org/10.1016/j.leukres.2016.09.005 0145-2126/© 2016 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/). study that compared both obinutuzumab combined with chlorambucil (GClb) and rituximab combined with chlorambucil (RClb) to chlorambucil (Clb) in newly diagnosed patients with CLL who required treatment. Median PFS was 26.7, 16.3 and 11.1 months for GClb, RClb and Clb, respectively [5] . The COMPLEMENT 1 study compared ofatumumab combined with chlorambucil (OClb) to Clb, and showed a median PFS of 22.4 and 13.1 months, respectively [6] . While a direct comparison between GClb and OClb is not available, it is possible to perform an indirect comparison since both the CLL11 and COMPLEMENT 1 trial included Clb as comparative treatment.
A comprehensive cost study among patients with CLL in the Netherlands showed that costs varied considerably between treatments, with Clb having the lowest total monthly costs [7] . The cost-effectiveness of GClb compared to RClb, OClb and Clb in the United Kingdom (UK) was calculated by Becker et al. [8] . However, these results might not be applicable to the Dutch context. First, input parameters such as drug prices and costs related to supportive care may not be similar. Second, guidelines for conducting economic evaluations in the Netherlands are different from the guidelines in the UK. For example, discount rates for effects and costs are different [9, 10] . Therefore, we aim to evaluate the cost-effectiveness of GClb compared to RClb, OClb and Clb in The Netherlands using an adjusted version of the UK model [8] .
Materials and methods
Evaluating the cost-effectiveness of treatments often requires modelling to bring together data sources and to extrapolate costs and effects over time. Modelling enables to compare all treatment options, not only the options that have been compared in a clinical study [11] . Modelling consists of several steps including creating a model structure (consisting of health states), assigning transition probabilities to each health state and selecting input parameters such as utility values and costs for each health state. Finally, sensitivity analyses are performed to examine the impact of assumptions and uncertainty across input parameters.
Model structure
A Markov model enables the study of the course of the disease by simplifying the disease course in health states. A Markov model including three mutually exclusive health states, i.e Progression Free Survival (PFS) (with/without therapy), Progression (Refractory/Relapsed lines) and Death ( Fig. 1 ) was developed by Becker et al. to assess the cost-effectiveness of GClb, RClb, Clb and other treatment options in the UK [8] . A country adaptation to the UK model was made to estimate the cost-effectiveness of these therapies in The Netherlands from a healthcare perspective (Table 1) .
Transition probabilities
Transition probabilities determine how patients move between health states in the Markov model. Transition probabilities from the PFS health state were derived from the CLL11 study. Observed Kaplan-Meier data was extrapolated using several parametric distributions (i.e. Exponential, Weibull, Log-logistic, Lognormal, Gamma and Gompertz). The goodness of fit of the distributions to the data was assessed using the Akaike Information Criterion (AIC), graphical assessment and knowledge of the expected extrapolation of PFS [8] .
To compare GClb with OClb, an indirect treatment comparison (ITC) was made using a fixed-effects network meta-analysis (NMA). Besides the CLL11, the COMPLEMENT 1 trial was included in this network. Table 2 provides an overview of the patient characteristics of the patients in CLL11 and COMPLEMENT 1. In the study by Becker et al. the natural logarithms of the estimated hazard ratios were used to inform the ITC (unpublished results). In the current study, two scenarios for the ITC were created. Besides the natural logarithms of the estimated hazard ratios (Scenario A), the observed median PFS was used to inform the ITC (Scenario B). The latter analyses were performed with an adapted version of the WinBUGS code of Dias et al. [12, 13] . Transition probabilities were supplemented with Dutch background mortality [14] .
Transitions probabilities from the Progression (Refractory/Relapsed lines) health state were obtained from the Dutch Population based HAematological Registry for Observational Studies (PHAROS-registry) [15, 16] . A population similar to the CLL11 population was selected from this registry by selecting patients with CLL (i.e. morphology code 9670 and 9823) who received first-line treatment with either Clb (N = 398) or RClb (N = 43). Since date of progression was frequently unavailable for patients in the PHAROS-registry, the start of second-line treatment was used as a proxy for all patients. Patients who did not receive a subsequent therapy after first-line therapy were excluded (N = 119), just as patients who have died during first-line therapy (N = 92). Table 2 provides an overview of the patient characteristics of the CLL11 study and the PHAROS-registry. To estimate the probability of transitioning from Progression to Death, a range of parametric survival distributions were compared. The distributions were assessed for their goodness of fit to the data using the AIC and Bayesian Information Criterion (BIC). Additionally, the parametric functions were assessed graphically. Finally, the impact of first-line treatment and prognostic factors (i.e. age, sex, Binet stage, WHO performance status and the number of comorbidities) on post progression survival (PPS) was tested. OS was significantly influenced by age and comorbidities. Prevalence of ≥2 comorbidities and/or age ≥65 years of the COMPLEMENT 1 (83%) was comparable to the PHAROS population (82%). However, the average number of comorbidities based on the cumulative illness rating scale in the CLL11 study was much higher. First-line treatment did not significantly influence OS, however, this could be related to the fact that only 10 of the 230 patients had received RClb as first-line treatment.
The PHAROS-registry has been approved by the Medical Ethics Committee of the Erasmus Medical Center Rotterdam (MEC-2011-200), The Netherlands (metc@erasmusmc.nl) that serviced as the Dutch Medical Ethics committee. The ethic committee decided that informed consent was not to be sought, as is the policy for the Netherlands Cancer Registration.
Health state utilities
Utility values generally range between 0 (death) and 1 (perfect health). The time a patient spent in each health state was weighted using the utilities provided by Kosmas et al. [17] . The values are presented in Table 1 and are in line with the cost-effectiveness model published by Becker et al. [8] .
Drug costs and drug administration costs
In the base case, drug costs were based on the planned dose based on average patient characteristics. Average weight and Body Surface Area were derived from the PHAROS-registry. The costs for entire vials were applied assuming no vial sharing. Obinutuzumab and ofatumumab are given in a fixed dose, and therefore do not depend on patient characteristics [5, 6] . Dutch drug costs were derived from reference price lists (i.e. Z-index).
The administration costs of obinutuzumab, rituximab or ofatumumab infusion were assumed to be equal to the costs of a day care treatment, and to be in accordance with the number of cycles [5, 6] . The model includes three mutually exclusive health states: 'progression-free survival (PFS) (with/without therapy)', 'progression (refractory/relapsed lines)' and 'death'. All patients start off in the initial treatment health state and can move to another health state or stay in the same state at the end of each subsequent analysis cycle. The possible transitions are indicated by the arrows [5] . The occurrence of adverse events was obtained from the CLL11 and COMPLEMENT 1 trials. According to the CLL11 study, adverse events (grade ≥3) occurred more frequently among patients treated with GClb (70%) and RClb (55%) compared to Clb (50%) [5] . The COMPLEMENT 1 trial revealed that 50% of the patients treated with OClb and 43% of the patients treated with Clb experienced an adverse event (grade ≥3) [5, 6] . Unit costs for anaemia (grade 3), febrile neutropenia (grade 3 and 4), neutropenia (grade 3 and 4) and thrombocytopenia (grade 3 and 4) were derived from the Dutch cost study by Bouwmans et al. [18] . The remaining unit costs for adverse events were obtained from a public database including data on average prices paid for health care products provided in Dutch hospitals (www.opendisdata.nl). Since health care products were not available for adverse events directly, the most appropriate health care product was identified based on expert opinion.
Supportive care costs
Costs of supportive care during PFS were derived from a study by Holtzer-Goor et al. [7] . In this study on real-world costs of CLL in The Netherlands, total monthly costs per treatment group are presented. Costs of chemo(immuno-) therapy and hospitalisations due to other reasons were excluded in order to prevent double counting in the model. We assumed that the total monthly costs of patients treated with Clb (N = 96) best represent the total monthly costs of patients treated with either GClb, RClb, OClb and Clb only.
Costs of supportive care during PD were also derived from the study by Holtzer-Goor et al. [7] . However, since this study included patients diagnosed between 1999 and 2003, treatment prescription might have changed. Therefore, the PHAROS-registry was used to provide more recent information on treatment prescription; costs derived from Holtzer-Goor were weighted using the distribution of treatments prescribed in second and subsequent lines as observed in the PHAROS-registry (Appendix A).
Sensitivity analyses
Deterministic sensitivity analyses were conducted to examine the impact of alternative input parameters on the incremental costeffectiveness ratio (ICER). The amount of drugs (without or with vial sharing and actual dose or planned dose), treatment duration (actual or according to label) and post progression mortality rate (age adjusted pooled post progression death rate from the PHAROSregistry or age adjusted pooled post progression death rate from CLL5 trial [19] as used by Becker et al. [8] ) were varied. Probabilistic sensitivity analysis (PSA) was performed to explore the joint uncertainty across all input parameters. In the PSA, probability distributions for input parameters were used instead of point estimates to reflect the uncertainty of these parameters. Input parameters were varied simultaneously and the model was run 10,000 times. The following input parameters were varied in the probabilistic sensitivity analysis (PSA); utilities, the HR derived from the ITC, parameters for the parametric PFS and PPS function, both the occurrence and costs of adverse events, weekly supportive care costs and administration costs.
Results
Model results showed that GClb was the most effective treatment strategy, life-years (LYs) were 6.45 while QALYs were 4.39 ( In all comparisons, the main cost drivers for the incremental costs are the drug costs of either obinutuzumab, rituximab or ofatumumab, and the costs of supportive care during progressive disease.
The results of the deterministic sensitivity analyses are presented in Table 5 . The ICERs, specifically those derived from the ITC, are sensitive to the utility assigned to the PFS health state (after treatment), treatment duration, i.e. whether the actual treatment duration or the treatment duration according to the label was implemented in the model, supportive care costs and postprogression mortality rate. ICERs are slightly influenced by the amount of drugs, i.e. without or with vial sharing and actual dose or planned dose. Also the post progression mortality rate had little influence on the ICERs.
The uncertainty around the total costs and QALYs as obtained from the probabilistic sensitivity analysis is shown by Fig. 2A and  B . Fig. 2A shows the comparison of GClb vs. Clb, RClb vs. Clb and GClb vs. RClb. This figure shows that GClb and RClb are more effective than Clb in 100% of the simulations. Compared to RClb, GClb is also more effective in 100% of the simulations. Fig. 2B shows the results from the PSA for GClb compared to OClb for scenario A and scenario B. GClb is more effective in 100% of the simulations in both scenario A and scenario B, and more costly in 65% and 71% of the simulations for scenario A and scenario B, respectively.
Discussion
This study evaluated the cost-effectiveness of GClb compared to RClb, OClb and Clb in The Netherlands. While ICERs for the UK were available, this study managed to calculate ICERs that are applicable to the Dutch health care setting by using Dutch input parameters. Furthermore, the RCT data was supplemented with real-world post-progression data to improve the generalisability of the results. While there is no official threshold in the Netherlands, the National Health Care Institute has defined categories of maximum additional costs per QALY depending on disease burden [20] . GClb is a cost-effective treatment option in the Netherlands for previously untreated patients with CLL and coexisting conditions given that the ICERs are below D 50,000 per QALY (i.e. the willingness to pay for the category with a disease burden between 0.41 and 0.7 [21] ). The ICER of GClb vs Clb was D 19,810 per LY and D 21,823 per QALY, and the ICER of GClb vs RClb was D 11,350 per LY and D 11,344 per QALY. In addition, the ITC showed that the ICER of GClb was favourable compared to OClb; the ICER ranged from D 6532 to D 17,364 per LY and D 6556 to D 16,180 per QALY. The sensitivity analyses showed the robustness of the results.
Since a direct comparison between GClb and OClb was not available, an indirect comparison was performed. This ITC has some limitations; first, only two trials were included and therefore it was not possible to account for heterogeneity between trials. Second, assumptions underlying the ITC were violated; the ITC assumes that the survival curves for the common comparator (i.e. CLB) are comparable. Although the inclusion criteria of the CLL11 and COM-PLEMENT 1 study were rather similar, patients in the COMPLEMENT 1 were slightly younger and had more often a Binet stage A. In addition, the dosing of Clb was different in the two trials. As a consequence, the median PFS of patients treated with Clb differed, i.e. 11.1 months in the CLL11 and 13.1 months in the COMPLEMENT 1 study. Potentially, the incremental effect of the intervention (i.e. GClb) could be larger if the comparative treatment is less effective. Furthermore, the ITC assumes that the proportional hazard assumption is not violated, while it seemed that the proportional A) B) hazard assumption does not hold over the full period. To overcome these limitations, a second scenario (Scenario B) was implemented using the median PFS to inform the ITC. Although this method does not overcome all limitations, we were able to provide a minimum and maximum ICER. Nevertheless, the ICER of GClb compared to OClb should be interpreted with caution and remains subject for further research.
PFS for all treatments was obtained from RCT data. Although RCTs are the golden standard for establishing efficacy, effectiveness in daily practice is influenced by many factors including patient characteristics and the context of health care delivery. Therefore, questions may arise to what extent the efficacy from the trial is generalisible to patients treated in daily practice. Although this is subject for further research, the generalisability regarding coexisting conditions was ensured since the CLL11 and COMPLEMENT 1 trial focused on this patient population. Furthermore, post progression survival (PPS) was obtained from real-world data, i.e. the PHAROS-registry. Ideally, PPS from the PHAROS-registry would have been calculated from the date of progression to match the model structure. However, the date of progression could not be retrieved from the registry and the start of second-line treatment was used instead. As a consequence, post progression survival was based on patients receiving second-line treatment and does not include untreated patients who progressed after first-line treatment. While using start of second-line treatment instead of progression probably underestimates PPS, excluding patients who have died before a second-line could have started may overestimate PPS.
Supportive care costs were derived from a Dutch study by Holtzer-Goor et al. [7] , and were easily applicable to the health states in the Markov model. Inclusion criteria for the study by Holtzer-Goor et al. and the CLL11 trial were a little different. All patients with CLL (except those suffering from another active malignant disease or another serious previous malignancy) were included in the study by Holtzer-Goor et al., whereas the CLL11 trial was conducted in patients with coexisting conditions. Patients in the study by Holtzer-Goor et al. were younger, and more often had a Binet stage A compared to the patients in the CLL11 study. Therefore, supportive care costs (both during PFS and PD) might have been underestimated. While this influences all treatment strategies, the potential underestimation of supportive care costs during PFS is more pronounced in treatment strategies with longer PFS (e.g. GClb) while the underestimation of supportive care costs during PD is more pronounced in treatment strategies with longer PD (e.g. Clb). Furthermore, total costs during PD might have been overestimated due to extrapolation of weekly supportive care costs in the model. Weekly costs were derived from the study by Holtzer-Goor based on a mean follow-up period of 6.4 years. However, in the model the weekly costs were applied until death. Finally, the distribution of treatments in the cost study of Holtzer-Goor et al. was adjusted to recently observed treatment patterns to calculate the costs of supportive care during PD; this assumes that the costs per treatment strategy will not change over the years and will still be representative.
Direct costs outside the health care system (including e.g. travelling expenses) were not taken into account just as indirect costs outside the health care system, such as costs associated to work days lost. Including travelling expenses was expected not to influence results since the costs associated to travelling to the hospital are very small compared to other costs such as drug costs or supportive care costs. Since the median age of the population in the CLL11 study was 73 years, we expected productivity costs also to be negligible.
Preferably, utility values should have been obtained from Dutch patients with CLL using the EQ-5D. However, since these are unavailable, utility values were obtained from a vignette study by Kosmas et al. [17] . One of the disadvantages of vignette studies is that people have their own interpretation of the health descriptions. For example, the health state further progression was valued with a higher utility value than PFS on second line therapy. Nevertheless, the limitations of the vignette study influence all treatment strategies.
Several differences exist between the base case results of the current study and the study by Becker et al. [8] . Total LYs and QALYs are higher in the current study. For example, LYs for GClb were 6.45 in the current study while LYs for GClb were 5.64 according to Becker et al. First, PFS is slightly higher in the current study due to a different discount rate for effects in the UK (3.5%) and The Netherlands (1.5%). Second, LYs in PD are substantially higher in the current study because post-progression was obtained from the PHAROS-registry. Nevertheless, post-progression was included in the deterministic sensitivity analyses (based on the CLL5 study as used by Becker et al. This revealed that although total LYs are influenced by this assumption, the impact on the ICER is small. In addition to differences for effects, total costs were much higher in the current study. For example, total costs for GClb were £34,375 (D 47,916) according to Becker et al., while total costs for GClb in the current study were D 110,969. This difference is caused by differences in monthly post-progression costs. In the current study, these costs were obtained from an observational study of Holtzer et al. and resulted in total progressive disease costs for GClb of D 69,467.
Becker et al. estimated total post-progression costs (according to the label and treatment protocol) for GClb to be £3765 (D 5248).
Conclusions
Although this cost-effectiveness analysis has its limitations, GClb currently appeared to be a cost-effective treatment strategy compared to RClb, OClb and Clb. Results of this study can be used to inform clinical guidelines and reimbursement decisions in The Netherlands, and help to choose the optimal treatment. Nevertheless, a direct comparison should be made to supplement the current evidence for GClb compared to OClb.
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